11:08 AM EDT, 06/23/2025 (MT Newswires) -- Lineage Cell Therapeutics ( LCTX ) said Monday its phase 1/2a trial of OpRegen showed consistent improvement in visual acuity for 36 months in a subgroup of patients with geographic atrophy.

In group four patients who have less advanced geographic atrophy compared with other groups, there was an improvement in visual acuity at 12 months, 24 months and 36 months, the company said.

Treated eyes in five patients with extensive OpRegen coverage showed a mean gain of +9.0 Early Treatment Diabetic Retinopathy Study letters at 36 months, up from +7.4 letters at 24 months, the company added.

The trial also showed sustained structural improvements in key retinal layers, the company said.

Shares of the company were up 9.5% in recent Monday trading.

Price: 1.04, Change: +0.09, Percent Change: +9.47